mProX™ Human FFAR2 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- GPCR Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human FFAR2 Stable Cell Line (S01YF-0923-PY67). Click the button above to contact us or submit your feedback about this product.
Elizabeth (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Anthony (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 Assessing FFAR2's impact on cellular processes in HOS cells exposed to acetic and propanoic acids.
HOS-GFP control cells, derived from HOS cells, and HOS-FFAR2 knockdown cells, obtained from HOS cells, were plated at a density of 1 × 10^5 cells on the upper chamber of Cell Culture Inserts in serum-free DMEM. These inserts were positioned in 24-well plates filled with 5% charcoal-stripped FBS-DMEM, with or without acetic acid and propanoic acid, in the lower chamber. Incubation occurred at 37 °C for 16 hours. The columns represent the average of three independent experiments, and error bars denote the standard deviation. ∗; p < 0.01 compared to cells untreated with acetic acid or propanoic acid. (AA, acetic acid; PA, propanoic acid).
Ref: Kurisu, Rio, et al. "Effects of free fatty acid receptor-2 (FFAR2)-mediated signaling on the regulation of cellular functions in osteosarcoma cells." Biochemical and Biophysical Research Communications 646 (2023): 56-62.
Pubmed: 36706706
DOI: 10.1016/j.bbrc.2023.01.067
Research Highlights
Gudneppanavar R, et al. "Epigenetic histone modification by butyrate downregulates KIT and attenuates mast ." Journal of cellular and molecular medicine, 2023.
Short-chain fatty acid butyrate has been shown to improve lung inflammation in mouse studies by inhibiting the activation of mast cells, which are responsible for initiating allergic responses. However, the exact mechanism of this regulation remains unclear. A recent study aimed to address this by examining the effects of butyrate on mast cells. The researchers found that butyrate treatment altered the histones of mast cells, inhibited histone deactetylase activity, and downregulated the receptor KIT, resulting in reduced mast cell proliferation and secretion of pro-inflammatory cytokines. This is thought to be due to butyrate acting as an HDAC inhibitor, rather than through its traditional receptors GPR41 and GPR43. Additionally, the study suggests that butyrate supplementation may have potential as a treatment for allergies and asthma through its epigenetic modifications of mast cells.
Pubmed:
37603611
DOI:
10.1111/jcmm.17924
Gao K, et al. "Oral administration of Bifidobacterium longum WHH2270 ameliorates type 2 diabetes ." Journal of food science, 2023.
A strain of Bifidobacterium longum, specifically WHH2270, has been shown to possess significant alpha-glucosidase inhibitory properties. This makes it a potential candidate for the treatment of Type 2 Diabetes Mellitus due to its ability to lower blood sugar levels. Additionally, its potential as a hypoglycemic agent is a promising avenue of research for the development of new treatments for T2DM. Further studies and clinical trials are necessary to confirm its efficacy and safety for use in managing the disease.
Pubmed:
37548634
DOI:
10.1111/1750-3841.16727
